Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jumped in today at 42.80 for a short ride. Nice close. Also, some nice news from Morningstar out after the bell: http://www.bloomberg.com/news/2012-01-18/transocean-abiomed-may-see-takeover-interest-morningstar-says.html
Takeover rumors always seem to spur some buying. Hopefully that's the case here too...
Yeah. As I put forth last week after hearing the last presentation, it seemed more geared toward the science side of the product. I postulated that the reason for that was probably the audience at this particular conference was more science-oriented versus the finance/investment oriented audience at other recent conferences.
At the moment, my focus is not on other indications but rather on how well the current product is selling. I'm eager to see the report from the end of last year and then what the report will be for the end of this quarter. If the results look promising, that should pull in more investors and get us off the bottom of the bowl so to speak. I would hope promising results would also yield a better financing situation in the middle of 2Q because that's obviously a huge concern for us all. We're bound to be diluted again, but by how much and on what terms are the questions.
Longer-term, expansion into other indications is where the money will be. But, we need to stabilize first.
Rick, yes that was the last presentation. Honestly, you didn't miss much if you didn't see it.
would be nice to completely fill the gap early next week.
On another note, we finally made it past .425 with a close at .43. We'll see if any buyers come thru tomorrow morning, but I'm hoping this is the beginning of a run past the 50MA.
Nope, he really did not go very in depth in this presentation. I believe it was a shorter presentation and the presentation was mostly generalities about laviv. There was not much discussion of anything related to financing, sales, etc. All in all, nothing was missed if you didn't catch the presentation.
Summary of Today's Presentation
In two words, nothing new.
291 physicians trained now with number increasing dramatically in the first quarter of this year.
More PR with appearances possibly on The View, Good Morning America, Access Hollywood and more.
That was pretty much the extent of any new info. If you listened and heard something I missed, post it.
It hasn't happened yet. It's only 9:45AM right now, so it starts in 15 mins. Go to: http://www.onemedplace.com/forum/webcast/#
GNTA is presenting right now, which is the presentation before ours.
ancil, to answer your question that you posted on another board...
correct, i have not been paying much attention.
Presentation is at 10AM PST and the link is http://www.onemedplace.com/ which loads fine for me. The presentation will supposedly be available throughout the rest of the week.
wow, that was a really great post. not sure i ever saw that post before. says a bit about the demand. too bad he doesn't post here more. i cannot stand looking at that yahoo board more than once per month.
closed up .02 at 42 cents. would sure be nice to get on the other side of 42 cents which has shown to be resistance over the last few weeks.
Please offer concrete statistics or credentials to back-up your opinion. Thank you.
It would seem the industry is trending towards offering a combination of treatment packages...
Realistically, the patient would only have to wait the first go-around. If I'm not mistaken, a patient's fibroplasts are stored for future procedures. And even if they were not stored, the patient could work with their physician to time future procedures accordingly.
As far as waiting on the first go-around, it definitely is a drawback. If/how this will affect sales, I cannot say. We'll probably be able to get a good idea in the next few months though.
DewDilligence, I'm not sure what weight you believe we think your analysis carries...
The entire basis of your point of view is predicated upon your opinion that there is not a demand for laviv. Can you offer any evidence to support your opinion? Are you an expert in analyzing dermatological products and/or market trends? Are you a dermatologist? Are you a plastic surgeon? Are you a fashion/beauty editor for a publication? Apart from simply stating your opinion, can you please provide some form of credentials to lend weight to your opinion?
Given that we are only in the first quarter of laviv being available, nobody can definitively say there is not a demand for laviv as there are simply not any statistics available yet.
We can only look to how experts in the beauty/dermatology/plastic surgery are reacting to the introduction of laviv. And from that standpoint, my observations are that laviv is receiving excellent coverage in beauty magazines and the number of doctors being trained continues to beat expectations. I can guarantee you editors would not waste space in their publications and doctors would not waste their time if they thought laviv would be a failure.
Now, can I definitively say that these early observations will translate into success? Of course not. But, until we receive at least a couple of quarters worth of data to gauge market demand, I think these are the best indicators we have. Trouble is, should the data lean positively, this boat will already be well on its way upriver for investors waiting for positive earnings to jump onboard. But, I'm sure I'd gladly sell them a life raft :)
lucky you. i have to wait a little longer for lower cap gains :(
i was hoping for info on the actual company...
does anyone have more info on the JV partner in China? I was trying to do a Google Search on them and really did not come up with much (at least in English)...
oh, yeah. definitely new cause i was just on the site last week. looks great. advertising UCLA and the JV.
no, there was not any mention if i recall.
haha...better yet, joan and melissa rivers! those two can never stop talking about anything, ever.
Nothing monumental stood out from the Oppenheimer presentation today, but a couple things I did notice.
First, in the Q&A, Pernock was asked about the orphan drug status rejection by the FDA. He said, the FDA felt there are more than 200,000 people suffering from restrictive burn scarring, which is the key criteria. He said they'll probably go back and debate the number, but he said if they're not approved, they'll present their protocols and do some sort of BLA. He said there seemed to be many in the agency that supported their pursuit in this area.
Second, the number of doctors trained is better than expected. On the last investor call, Pernock noted that 154 doctors had been trained thus far and he expected to have 270 trained by the end of the year. During the presentation today, he noted that 104 more doctors were trained thru December 6th, bringing the total to 258. He also revised the 270 figure up to 300-315 by the end of the year and 1000 doctors fully trained by the end of 1Q2012. So it would appear more and more momentum is building. The more doctors, the more potential patients/customers ;)
I'll assume that is a joke...
agreed it can't be compared...but for a different reason...didn't the company basically say it was abandoning the approach the patent outlines?
Why advertise your failings? You release disappointing news as discreetly as possible and move on. To bring more attention than required would not make any sense.
Obviously the news is disappointing because the benefits provided by receiving orphan drug status would have been nice. But, the FDA rejected the application because the drug can be used too broadly -- probably a good sign.
Was anybody able to watch the presentation?
As CSD responded, yes, "everyday" folks could short penny stocks. You have to use certain brokers that most people do not use (Interactive Brokers is one of the more well-known). The commonly used discount brokers (Etrade, Ameritrade, Scottrade, etc. do not allow their customers to short pennies.) Even these brokers do not always have shares available to short. There has been a large trend (for obvious reasons) in shorting stocks, especially biotech. Timothy Sykes has made quite a reputation doing that.
you don't know that there were more buyers than sellers. the only information you have is at what price the trades went thru. in other words, you only know the number of trades that went thru at the ask and at the bid. the MMs may very well may decide to fill orders at the ask or bid. generally speaking, you are correct. but, it's a generalization.
Not sure what "visual updates" you are expecting to receive any time soon given we found out just last month they won't have any new prototypes for months.
As I said when we first heard, the announcement of the RS months before any significant developments were to occur completely suffocated this stock. Frankly speaking, it was amateur for management not to realize the full negative impact the announcement would have. By time time they move forward with the RS, they'll be lucky to get the PPS back to where it was prior to announcing a RS. The shareholder meeting should have had a positive impact on the PPS and it was completely marginalized by the looming RS. Not sure who would invest in a stock without any significant events occurring until after a RS is initiated.
Unfortunately, I do not believe you can infer any sort of conclusion from what he said. Is a partnership a possibility? Sure. But, at this point, I'm not very positive on the likelihood of it happening soon. Fortunately, I think they have sufficient cash on hand for long enough for us to see where this will be heading, but I'm also wary of any deal that may dilute my investment.
Good luck to you too. Not sure why you would pull your investment as soon as the company is actually making progress, but I guess you need the money...
As for the claims about FCSC not reporting income in 3Q and therefore something is wrong, this interpretation makes zero sense. How could they report income when they only rolled out in the last month of 3Q and they are not paid until the procedure is completed, which takes weeks? If you review previous posts, most (if not all) of us expected to not see any revenue reported until we receive the 4Q 2011 report in 1Q 2012 at the earliest.
laltrader did a good job highlighting the important points made on the call. I took note of most of the same updates, including:
1) The trial doctor for the acne scarring mostly reviewed his study, but the most interesting answer he gave to a question was that 80% of all treatment in dermatology is off-label. He said he would be remiss not to mention to a patient with acne scarring that LaViv was available, even before FDA formally approves it. He also said LaViv probably would receive a favorable view from the FDA on pursuing the indication for acne due to it being such a large problem. For the naysayers (Dew), you've tried to make a big point about the fact that FCSC will be bankrupt before they ever get acne treatment off the ground and there is still a long way to go to meet approval from the FDA, but based upon the evidence this doctor provided, looks like it really won't matter because they'll be using it off-label until they get approval anyways.
2) Should hear from FDA on orphan drug status for burn/vocal chord scarring in "weeks".
3) Personalized skin cream available in 1Q 2012.
4) To date, 154 doctors received certification to provide LaViv with 60 doctors trained in the last week alone. Expect to have 270 doctors trained by the end of the year.
5) 105 biopsies in progress. "Not much" revenue being generated from these biopsies as the doctors are receiving the product at a lower rate to build momentum for the product.
6) At national dermatology conference, only 3 products were offered a "Hot Topic" session. The LaViv session was standing room only, while the other 2 products that were given a session were not nearly as well attended.
7) Finally, someone asked a question on financing, but Pernock did not give much insight. Only that "all offers were on the table."
8) Lots more publicity coming down the pipeline.
9) Feel that their IP is well protected, but filed for patent extension. Will hear whether they are approved early-mid next year.
My overall interpretation is that I am excited to see how many doctors are getting onboard and am encouraged by the progress. It sounds like there could be some more good news before the end of the year. As I said a couple of months ago, I'm not expecting much in the way of results until after mid next year, but I'm comfortable with my investment. I've thought about investing more, but my only concern right now is financing.
yeah, volume has gone up slightly the last couple of days, but not much to write home about. it really needs to break above the 50MA and that would be a terrific catalyst. hopefully there will be some sort of catalyst on the conference call today to make that happen.
closed at the 50MA. hopefully this will be the week we break to the upside...
would be nice to see some buyers so we can break to the upside of the 50MA rather than to the downside as we have been. that would probably mark a nice turning point.
I have absolutely no clue what you are asking or talking about -- your post does not make sense.
You can go back to any TDCP post that was not deleted by doing a keyword search or scanning thru all of the old posts -- there are 50 posts per page so you can just keep hitting the "Older" button until you find the post you are looking for.
When I delete a post, I provide the reason as to why the post has been deleted. The majority of posts I have deleted on this board are either off-topic or include vulgarity/personal attacks. I do NOT delete posts with any information relating to TDCP whether I agree with it or not (unless it includes vulgarity, personal attacks, etc.).
Today, some of your posts were deleted because you were effectively spamming the board and saying the same thing over and over again. I am trying to make this board as valuable all members as possible whether you are pro or against TDCP. I hope you can understand that.
I'll consider this topic closed and any future posts relating to this will be deleted for being off-topic.
Interesting news. Glad to hear about the progress. Is anyone familiar with how great of an improvement this is? Is a 1 point or 2 point improvement significant? How does this relate to the improvement provided by lasers? Any comments from those who are more knowledgeable about these treatments?
Volume is light and the news does not seem to have proven to be a strong catalyst in moving the price. But maybe people just have not seen it yet.